Detalhe da pesquisa
1.
Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
J Hepatol
; 77(5): 1422-1430, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35752223
2.
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
J Hepatol
; 70(5): 1008-1015, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982526
3.
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
J Viral Hepat
; 26(1): 118-125, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187599
4.
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
J Viral Hepat
; 26(9): 1040-1049, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30972912
5.
Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey.
Liver Int
; 39(7): 1355-1362, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30500104
6.
Treatment of hepatitis B: Is there still a role for interferon?
Liver Int
; 38 Suppl 1: 79-83, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29427498
7.
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.
Liver Int
; 38(3): 417-423, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28732143
8.
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Liver Int
; 35 Suppl 1: 107-13, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25529095
9.
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
Hepatology
; 57(3): 890-6, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22473858
10.
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Liver Int
; 34 Suppl 1: 120-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24373088
11.
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Gut
; 62(2): 290-8, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22859496
12.
Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Liver Int
; 33 Suppl 1: 157-63, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23286860
13.
Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
J Hepatol
; 56(6): 1239-46, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22326467
14.
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.
J Hepatol
; 56(5): 1006-1011, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22245886
15.
The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy.
Hepatology
; 61(5): 1459-61, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25645624
16.
Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.
Liver Int
; 31 Suppl 1: 90-4, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205144
17.
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
PLoS One
; 15(4): e0230893, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32275726
18.
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
Antivir Ther
; 14(6): 789-96, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19812441
19.
[Not Available].
Hepatology
; 57(3): 1283-4, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22707216
20.
Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.
Antivir Ther
; 24(2): 133-140, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865588